Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ivuxolimab · PF-8600

Bispecific antibody · Immune activation, directed at OX40 (TNFRSF4) · developed by PFIZER

Phase 3 Most advanced trial
PFE Developer

What is Ivuxolimab?

Ivuxolimab is an agonistic antibody that binds and activates OX40 (TNFRSF4), a costimulatory receptor on T lymphocytes, promoting proliferation of memory and effector T cells. It is studied in advanced malignancies, non-small cell lung cancer, ovarian cancer, urothelial cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-8600, PF04518600
Drug type
Bispecific antibody
Targets
OX40 (TNFRSF4)
Mechanism
Immune activation, directed at OX40 (TNFRSF4)
Pathways
T-cell activation, T-cell proliferation
Therapy area
Oncology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
APS3IS9D6W

Conditions studied

Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer

Other drugs acting on TNFRSF4

More from PFIZER

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Ivuxolimab

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.